A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.
Collecting images of suspicious-looking skin growths and sending them off-site for specialists to analyze is as accurate in identifying skin cancers as having a dermatologist examine them in person, a new study shows.
